Empagliflozin in Heart Failure with a Preserved Ejection FractionStefan D. Anker, Milton Packer, Martina Brueckmann et al.|New England Journal of Medicine|2021Cited by 4.6k
Patient Phenotype Profiling in Heart Failure with Preserved Ejection Fraction to Guide Therapeutic Decision Making. A Scientific Statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of HypertensionStefan D. Anker, Giuseppe Rosano, Muhammad Usman et al.|European Journal of Heart Failure|2023Cited by 187
Precipitating Factors and 90-Day Outcome of Acute Heart Failure: A Report from the Intercontinental GREAT RegistryMattia Arrigo, Alexandre Mebazaa, Étienne Gayat et al.|European Journal of Heart Failure|2016Cited by 149
Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved TrialStefan D. Anker, Milton Packer, Javed Butler et al.|European Journal of Heart Failure|2020Cited by 135
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trialMilton Packer, Faı̈ez Zannad, Stefan D. Anker et al.|European Heart Journal|2020Cited by 135